What Egualia does

Egualia - Industrie Farmaci Accessibili (formerly Assogenerici, founded 1993) is the official Italian industry association representing pharmaceutical companies that produce generic equivalent medicines, biosimilars, and Value Added Medicines. Headquartered in Rome, the association represents over 60 member companies operating nearly 40 production sites and employing approximately 10,000 workers across Italy, and is documented as accounting for over 50% of generic equivalent medicines produced domestically in Italian facilities. Egualia operates as a non-profit trade body rather than a commercial enterprise; it is funded through recurring membership dues and delivers its value through three core representation services: generic equivalent medicines advocacy, biosimilar representation (coordinated through its dedicated Italian Biosimilars Group / IBG sub-association), and Value Added Medicines promotion (coordinated through its VAM Group). Supporting these services, the association runs the Osservatorio Egualia research program in partnership with NOMISMA, publishes market studies, regulatory updates, and transparency lists, and operates public-facing initiatives such as the Fabbriche Aperte (Open Factories) program and the 'Io Equivalgo' awareness campaign in partnership with Cittadinanzattiva.

Its go-to-market is community- and policy-led: the association engages Italian and European institutional stakeholders (notably AIFA and EMA), coordinates joint advocacy across members, and participates in the European-level Medicines for Europe network and the global IGBA. Distribution of the underlying medicines is handled by members through standard Italian channels — community pharmacies, hospital pharmacy tenders, and regional health authority procurement — not by Egualia itself. The association has documented that the off-patent industry it represents has contributed over 4 billion EUR in savings to public pharmaceutical expenditure in Italy since the 2000s, a figure the association uses as its primary policy-impact argument.

Operationally, Egualia runs a small staff (11-50 per firmographic data), has no external investors or parent company, and is governed by a Consiglio di presidenza, Consiglio direttivo, and Collegio dei probiviri. There is no disclosed product pricing, no software platform, no API, and no AI/ML capability; its competitive position rests on regulatory expertise, institutional access, and the collective network effects of its membership rather than on proprietary technology.

Name

Egualia

Legal name

Egualia Industrie Farmaci Accessibili

Website

https://egualia.it

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Egualia is the Italian industry association representing 60+ pharmaceutical companies producing generic, biosimilar, and Value Added Medicines. Founded in 1993 and headquartered in Rome, it advocates for member companies and engages AIFA, EMA, and the Italian National Health Service.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

akta.pro secondary industry

Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance) (HLAAAHAJ)

Keywords

• Pharmaceutical industry association
• Generic equivalent medicines
• Biosimilar medicines
• Value added medicines
• Pharmaceutical policy advocacy

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Association membership dues: Egualia operates as a non-profit industry association funded by membership dues from pharmaceutical companies producing generic medicines, biosimilars, and Value Added Medicines in Italy.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Egualia is an Italian non-profit industry association (associazione) representing pharmaceutical companies that manufacture generic equivalent medicines, biosimilars, and Value Added Medicines in Italy. The association delivers representation, regulatory advocacy, market research, stakeholder coordination, and policy development to its member companies, and conducts public awareness activities to promote access to affordable medicines in the Italian healthcare system.

Product overview

Egualia (formerly Assogenerici) is Italy's official industry association representing pharmaceutical companies manufacturing generic equivalent medicines, biosimilars, and Value Added Medicines. The organization does not offer a unified software product but rather operates as a multi-faceted association providing three core representation services through specialized sub-groups: the Italian Biosimilars Group (IBG) for biosimilar advocacy, the VAM Group for Value Added Medicines, and general generic equivalent medicines representation. Supporting these core services, Egualia maintains the Osservatorio Egualia initiative for market research and trend analysis, publishes regular studies and reports on pharmaceutical markets, and runs educational initiatives like the Fabbriche Aperte program. The association connects member companies with Italian and European institutions to develop sustainable pharmaceutical policies.

Differentiator

Problem solved

Functional benefit

Products and services

• Italian Biosimilars Group (IBG) Specialized sub-group within Egualia for member companies focused on biosimilar medicines, providing regulatory expertise, market studies, advocacy for biosimilar adoption, and stakeholder coordination in the Italian healthcare system.
• VAM (Value Added Medicines) Group Specialized sub-group within Egualia dedicated to Value Added Medicines, representing member companies engaged in repositioning or reformulating existing molecules to create additional therapeutic value, with associated advocacy and market development support.
• Osservatorio Egualia Research and analysis service producing scenarios and trend reports on accessible medicines markets in Italy, including policy analyses, market studies, transparency lists, and patent expiration tracking, delivered in collaboration with economic research institute NOMISMA.
• Studies and Analysis Reports Periodic publications from Egualia covering the Italian and European generic and biosimilar medicines markets, including the annual Italian generic medicines market report, biosimilar market analyses, European comparisons, transparency lists, and patent expiration tracking.

Quantifiable outcome

• Without the generic pharmaceutical industry, public drug expenditure would have been over 4 billion EUR higher
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and supporting.

• Medicines for EuropecoreStrategic or Co-development PartnerEgualia is a member of Medicines for Europe (formerly EGA), the European industry voice for generic equivalent, biosimilar, and Value Added Medicines producers. Medicines for Europe represents 350 production and research sites with 160,000 employees across Europe.
• IGBA - International Generic and Biosimilar Medicines AssociationcoreStrategic or Co-development PartnerEgualia is affiliated with IGBA, the global association representing generic and biosimilar medicine manufacturers worldwide.
• NOMISMAsupportingStrategic or Co-development PartnerEgualia collaborates with NOMISMA, an Italian economic research institute, on the annual Osservatorio Egualia report analyzing affordable medicine markets and trends from 2015-2025.
• CittadinanzattivasupportingStrategic or Co-development PartnerEgualia partners with Cittadinanzattiva, an Italian civic participation organization, on the 'Io Equivalgo' public awareness campaign about generic medicines.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Japan Generic Medicines Association: Japanese trade association for generic medicines manufacturers. Directly analogous to Egualia as a national-level industry body, though focused on the Japanese market.
• Association for Accessible Medicines (AAM, USA): US-based association for generic and biosimilar manufacturers. Comparable to Egualia in representing affordable-medicines producers through policy advocacy, though operating under a different healthcare system.
• Pro Generika (Germany): German association for generic and biosimilar medicines manufacturers. Closely mirrors Egualia's advocacy and regulatory engagement model within the German market context.
• AESEG (Asociación Española de Medicamentos Genéricos): Spanish national association representing generic pharmaceutical manufacturers. Highly comparable in structure, mission, and advocacy scope to Egualia, but operating in Spain rather than Italy.
• BGMA (British Generic Manufacturers Association): UK trade body representing manufacturers of generic and biosimilar medicines. Mirrors Egualia's mission in advocating for affordable medicines through regulatory and policy engagement in the UK.
• Canadian Generic Pharmaceutical Association (CGPA): Canadian national association representing generic pharmaceutical manufacturers. Comparable in scope and advocacy function to Egualia within the Canadian regulatory and reimbursement environment.
• GEMME (France - Association des Génériques et Biosimilaires): French trade association for generic and biosimilar medicines producers. Directly analogous to Egualia in mandate and stakeholder engagement, operating in the French market.

Direct peers

• IGBA - International Generic and Biosimilar Medicines Association: Global umbrella association for generic and biosimilar medicines manufacturers. Egualia is an affiliated national member, sharing identical advocacy objectives at the international level.
• Medicines for Europe: European-level trade association representing generic, biosimilar, and value added medicines manufacturers across 350 production/research sites. Egualia is a direct national member, making Medicines for Europe its closest peer in mission and constituency.

Broad incumbents

• Farmindustria: Italian pharmaceutical industry association representing the full pharma sector including originator companies. Operates in the same policy and institutional engagement space as Egualia but covers branded, generic, and biotech players collectively.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/egualia

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Egualia